Clinical Trial Update: S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating S1211 consisting of bortezomib, dexamethasone, and lenalidomide with or without elotuzumab for newly diagnosed high-risk multiple m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Elotuzumab (elotuzumab)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-10-27